Receptor Guided 3D-QSAR: A Useful Approach for  Designing of IGF-1R Inhibitors by Muddassar, M. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2008, Article ID 837653, 9 pages
doi:10.1155/2008/837653
ResearchArticle
Receptor Guided 3D-QSAR: A Useful Approach for
Designing of IGF-1R Inhibitors
M. Muddassar, F. A. Pasha, H. W. Chung, K. H. Yoo, C. H. Oh, and S. J. Cho
Future Fusion Technology Division, Computational Science Center, Korea Institute of Science and Technology,
P.O. Box 131, Cheongryang, Seoul 130-650, South Korea
Correspondence should be addressed to S. J. Cho, chosj@kist.re.kr
Received 16 August 2007; Accepted 17 December 2007
Recommended by Daniel Howard
Research by other investigators has established that insulin-like growth factor-1 receptor (IGF-1R) is a key oncological target,
and that derivatives of 1, 3-disubstituted-imidazo[1,5-α] pyrazine are potent IGF-1R inhibitors. In this paper, we report on our
three-dimensional quantitative structure activity relationship (3D-QSAR) studies for this series of compounds. We validated the
3D-QSAR models by the comparison of two major alignment schemes, namely, ligand-based (LB) and receptor-guided (RG)
alignment schemes. The latter scheme yielded better 3D-QSAR models for both comparative molecular ﬁeld analysis (CoMFA)
(q2 = 0.53, r2 = 0.95) and comparative molecular similarity indices analysis (CoMSIA) (q2 = 0.51, r2 = 0.86). We submit that
this might arise from the more accurate inhibitor alignment that results from using the structural information of the active site.
We conclude that the receptor-guided 3D-QSAR may be helpful to design more potent IGF-1R inhibitors, as well as to understand
their binding aﬃnity with the receptor.
Copyright © 2008 M. Muddassar et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The insulin-like growth factor-1 receptor is a membrane-
associated receptor that belongs to subclass I of the recep-
tor tyrosine kinase (RTK) superfamily [1]. IGF-1R has been
shown to have signiﬁcant roles in the regulation of normal
cell growth. It has mitogenic and survival eﬀects on human
cancer cells [2]. The Binding of IGF-1 to IGF-1R activates
the RTK, and later, in turn, activates a cascade of down-
stream signals, which are postulated to stimulate cell prolif-
erationandenhanceresistancetoapoptosis [3].Understand-
ably, the abnormal expression of the IGF-1R has been im-
plicated to cancer. Epidemiological studies have also shown
a link between serum concentrations of IGF-1 and IGFBP-3
with increased risks of breast cancer [4]. A number of anti-
cancer agents which inhibit the IGF-1R activity and prolifer-
ation [5] have been extracted from plants [6]a sw e l la ss y n -
thesized, such as BMS-554417 (2-(4-substituted-2-oxo-1,2-
dihydropyridin-3-yl)-benzimidazole) [7] and NVP-AEW541
(pyrrolo[2,3-d] pyrimidine derivative) molecules. Both of
these compounds are orally administered and have proved
antitumor activity. Various QSAR techniques are being used
to explore more potent ligands [8–11]; but in this study,
we performed comparative three-dimensional quantitative
structure activity relationship (3D-QSAR) [12–14]a n a l y -
ses on IFG-1R inhibitors [15] of imidazo [1, 5-α] pyrazine
derivatives. In 3D-QSAR [14], determination of the bioac-
tive conformer [16] and molecular alignment of the com-
pounds is key factor to get meaningful results. The biologi-
callyactiveconformationsofthestructuresshouldbealigned
in a way that represents a similar binding mode [17]. Here
we ﬁrst applied the ligand-based (LB) strategy using the sys-
tematic search-based minimum energy conformer approach
[18]. Second, receptor-based 3D-QSAR [19] using molecu-
lar docking of inhibitors in the available X-ray crystal struc-
ture [20] of the receptor protein. The qualities of these 3D-
QSAR models were compared and discussed with respect to
the IGF-1R target.
2. MATERIAL AND METHODS
A series of 54 potent 1, 3-disubstituted imidazole [1, 5-α]
pyrazine derivatives with their inhibitory activities to IGF-
1R were taken from the literature [15]. The dataset was ran-
domly divided into 43 and 11 molecules, the training and
testdatasets,respectively.TheobservedIC50 valueswerecon-
verted into pIC50 values and are reported in Table 1.2 Journal of Biomedicine and Biotechnology
Table 1: The structures and observed IGF inhibitory activities [15].
No. Structure R IC50 (M) pIC50
1 A 4-OBn 1.97 ×10
−6 5.706
2 A 3-OH 0.518 ×10
−6 6.286
3 A 3-OBn–4-OMe 1.35 ×10
−6 5.870
4 A 3-OBn–4-OH 3.31 ×10
−6 5.480
5∗ B Cyclopentyl 3.5 ×10
−6 5.456
6 B Cyclohexyl 1.05 ×10
−6 5.979
7∗ B– C H 2–cyclopropyl 2.27 ×10
−6 5.644
8∗ B– C H 2–cyclohexyl 1.11 ×10
−6 5.955
9B – C H 2CH2OMe 6.28 ×10
−6 5.202
10 B –CH2–2-pyridyl 1.09 ×10
−6 5.963
11 C H 0.606 ×10
−6 6.218
12 C 2-F 0.224 ×10
−6 6.650
13 C 3-F 0.51 ×10
−6 6.292
14 C 4-F 1.23 ×10
−6 5.910
15 C 2-Cl 0.343 ×10
−6 6.465
16 C 3-Cl 2.12 ×10
−6 5.674
17∗ C 4-Cl 0.980 ×10
−6 6.009
18 C 2-OCF2H3 . 2 8 ×10
−6 5.484
19 C 3-OCF2H5 . 7 8 ×10
−6 5.238
20 C 4-OCF2H2 . 8 2 ×10
−6 5.550
21 C 2,3-Diﬂuoro 0.898 ×10
−6 6.047
22 C 3,4-Diﬂuoro 4.48 ×10
−6 5.349
23∗ C 2,5-Diﬂuoro 0.329 ×10
−6 6.483
24 C 2,6-Diﬂuoro 0.215 ×10
−6 6.668
25 C 3,5-Diﬂuoro 1.35 ×10
−6 5.870
26 C 2,6-Dichloro 1.67 ×10
−6 5.777
27 C 2-Cl,6-F 0.248 ×10
−6 6.606
28 D Cyclopentyl 1.05 ×10
−6 5.979
29 D Cyclohexyl 3.51 ×10
−6 5.455
30 D Cycloheptyl 3.79 ×10
−6 5.421
31∗ D Phenyl 1.68 ×10
−6 5.775
32 E trans-NH2 0.221 ×10
−6 6.656
33 E cis-NH2 0.775 ×10
−6 6.111
34∗ E trans-NHMe 0.105 ×10
−6 6.979
35 E trans-Pyrrolodinyl 1.82 ×10
−6 5.740
36∗ E trans-Piperidinyl 3.40 ×10
−6 5.469
37 E trans-NHPh 1.30 ×10
−6 5.886
38 E trans-NHBn 1.39 ×10
−6 5.857
39 F trans-NH2 0.119 ×10
−6 6.924
40 F cis-NH2 0.228 ×10
−6 6.642
41 F trans-N(Et)2 0.115 ×10
−6 6.939
42 F trans-Azetidinyl 0.081 ×10
−6 7.092
43 F trans-Pyrrolidinyl 0.103 ×10
−6 6.987
44∗ F trans-Morpholino 0.091 ×10
−6 7.041
45∗ G trans-Pyrrolidinyl 0.116 ×10
−6 6.936
46 G cis-Pyrrolidinyl 0.089 ×10
−6 7.051
47 G cis-NH2 0.060 ×10
−6 7.222
48 G cis-NMe2 0.166 ×10
−6 6.780
49∗ G cis-Piperidinyl 0.237 ×10
−6 6.625
50 G cis-Morpholino 0.148 ×10
−6 6.830
51 G cis-NH-iPr 0.220 ×10
−6 6.658
52 G cis-N(Me)-Piperizinyl 0.265 ×10
−6 6.577M. Muddassar et al. 3
Table 1: Continued.
No. Structure R IC50 (M) pIC50
53 H trans-NH2 0.526 ×10
−6 6.279
54 H cis-NH2 0.554 ×10
−6 6.256
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2.1. Computationaldetails
The molecular modeling studies were carried out using
SYBYL 7.3. The initial structures were minimized at Tri-
pos force ﬁeld [21] with MMFF94 charge by using conju-
gate gradient method, and convergence criterion was 0.005
kcal/mol.The comparative molecular ﬁeld analysis (CoMFA)
andcomparativemolecularsimilarityindicesanalysis(CoM-
SIA) studies require aligned structures [16]. The ligand-
based (LB) and receptor-guided (RG) alignment techniques
were used in two geometrical schemes respectively.
2.2. CoMFAandCoMSIA
Lennard-Jones and Coulomb potentials-based CoMFA anal-
ysis has been performed and the steric as well as electrostatic
energieswerecalculatedbyusingsp3 carbonprobeatomwith
Van der Waal radius of 1.52 ˚ A and +1 charge. The energies
were truncated to ±30kcal/mol and the electrostatic contri-
butions were ignored at lattice interactions with maximum
steric interactions. The CoMFA were generated by standard
method in SYBYL. The CoMSIA models were also derived
with the same lattice box used as in CoMFA calculations.
All ﬁve CoMSIA similarity indices (steric, electrostatic, hy-
drophobic, H-bond donor, and H-bond acceptor) were eval-
uated using the probe atom. The CoMSIA models from hy-
drophobic and H-bonds were calculated between the grid
point and each atom of the molecule by a Gaussian function
[14]. An attenuation factor’s default value of 0.30 was used,
which is the standard distance dependence of molecular sim-
ilarity.
2.3. PLSanalysisandvalidationofQSARmodels
In order to derive 3D-QSAR models, the CoMFA and CoM-
SIA descriptors were used as independent variables and
the pIC50 values as the dependent variable. Partial least-
square(PLS)method[22]wasusedtolinearlycorrelatethese
CoMFA and CoMSIA descriptors to the inhibitory activity
values. The CoMFA cutoﬀ values were set to 30kcal/mol
for both steric and electrostatic ﬁelds, and also all ﬁelds
were scaled by the default options in SYBYL. The cross-
validation analysis was performed using the leave one out
(LOO)methodinwhichonecompoundisremovedfromthe
dataset and its activity is predicted using the model derived
from the rest of the dataset. The cross-validated correlation
coeﬃcient (q 2) that resulted in optimum number of compo-
nentsandloweststandarderrorofpredictionwerecalculated
using the following formulae,
q2 = 1 −

y

ypred − yobserved
2

y

yobserved − ymean
2,
PRESS =

y

ypredicted − yobserved
2,
(1)
where γpred, γactual,a n dγmean are predicted, actual, and mean
values of the target property (pIC50), respectively. The non-
cross-validated PLS analyses were performed with column
ﬁltering value of 2.0, to reduce analysis time with small eﬀect
ontheq 2 values.Tofurtherassesstherobustnessandstatisti-
cal conﬁdence of the derived models, bootstrapping analysis
for 100 runs were performed.
The predictive power of 3D-QSAR models, derived by
using the training set were examined by an external test set
of eleven molecules. The predictive ability of the models is
expressed by the predictive r 2 value, which is analogous to
cross-validated r 2 (q 2) and is calculated using the following
formula:
r2
pred =
SD −PRESS
SD
,( 2 )
where SD is the sum of the squared deviations between the
biological activities of the test set and mean activities of the4 Journal of Biomedicine and Biotechnology
training molecules and PRESS is the sum of squared devi-
ation between predicted and actual activities of the test set
molecules.
3. RESULTS AND DISCUSSION
3.1. Ligand-basedalignment
In this scheme, the most active molecule was used as a tem-
plate. Systematic search routine was used in the conforma-
tional analysis and all rotatable bonds were searched in 10
◦
increments from 0◦ to 350
◦. Conformational energies were
computedwithelectrostaticterm,andthelowestenergycon-
former was selected. The template was modiﬁed for other
ligands of the series. All ligands were minimized by Tripos
force ﬁeld but the common moiety was constrained during
minimization. The molecules were aligned by superimpos-
ing common substructures using SYBYL database alignment
option. These aligned structures were subsequently used for
ligand-based CoMFA/CoMSIA probe interaction energy cal-
culations.
3.2. Receptor-guidedalignment
This geometrical scheme is based on docked geometry. The
best docked mode of the smallest compound was taken
as template and modiﬁed for the other compounds. The
compounds were minimized by Tripos force ﬁeld (Pow-
ell method, 2000 iterations, and 0.05kcal·mol−1·˚ A−1 en-
ergy gradient convergence criteria). All minimized struc-
tures at this binding mode were superimposed to get the
molecular alignment for CoMFA and CoMSIA. The super-
imposed structures inside the receptor site were further used
for CoMFA and CoMSIA analysis.
3.3. Moleculardocking
The structure coordinates of IGF-1R were obtained from
protein databank (1JQH) [20]. Recently, Mulvihill et al. [15]
presented a possible binding mode of compound-2 by using
FlexX-based docking. Here we have also performed molec-
ular docking of same compound. The PDB ﬁle obtained
from protein data bank was used as receptor site. All wa-
ter molecules were removed and the protein was modiﬁed
to dock inhibitor. The active site was deﬁned with a distance
of 6.5 ˚ A of ATP binding site. The ligand-2 was docked into
the monomer unit (A) of IGF-1R and out of 100 conformers
the best mode was selected as template. This binding mode
seemsprominentasthehydrophobiczoneofinhibitorcorre-
sponds to hydrophobic pocket of IGFR. The residue E-1080,
M-1082, K-1033, D-1086, G-1006, and L-1005 makes hinge
contact and might have signiﬁcant role in the inhibition of
IGF-1R. It is also clear from all the ﬁgures that the depicted
mode holds 3 H-bonds in this region. The –OH group of
benzene ring makes H-bond with –NH of K-1033, nitrogen
of pyrimidine ring makes contact with –NH of M-1082 and
both act as H-bond acceptor. The NH2 group of pyrimidine
ring acts as H-bond donor and makes contact with oxygen of
E1080.
3.4. CoMFAandCoMSIAresults
The CoMFA and CoMSIA studies were carried out by using
both geometrical schemes with diﬀerent descriptors ﬁelds
independently and in combination. The ligand-based align-
ment gave better results for CoMFA model using both ﬁeld
descriptors with cross-validated r2(q2) = 0.52 and non-
cross-validated r2 = 0.88, while for CoMSIA model, combi-
nation of steric, electrostatic, and H-bond acceptor yielded
the best statistical values with q2 = 0.42 and r2 = 0.80.
TheinternalpredictivityoftheseCoMFAandCoMSIAmod-
els was also good with boot-strapped correlation coeﬃcient
r2
bs = 0.91 and 0.85, respectively. These models were also val-
idated on a test set of 11 molecules with predictive r2 = 0.67
for CoMFA model and 0.57 for CoMSIA model. In compar-
ison to LB, receptor-guided alignment yielded more signif-
icant models with better understanding of these inhibitors
and receptor interactions. Best CoMFA models were ob-
tained by combination of steric and electrostatic ﬁeld de-
scriptors with q2 = 0.53 and r2 = 0.95. Whereas steric,
electrostatic, and H-bond acceptor ﬁled descriptors gave the
best CoMSIA model with q2 = 0.51 and r2 = 0.86. To
further asses the robustness and statistical conﬁdence, the
boot strapping analysis were performed for 100 runs. The
r2
bs for CoMFA = 0.97 and CoMSIA = 0.90 models suggest
that a good internal consistency exists within the underly-
ing dataset. The high r2 predictive values for CoMFA and
CoMSIA (0.67 and 0.64, resp.) also prove models validity. In
our eﬀorts to obtain the more pronounced model, region fo-
cusing was performed. It only yielded high q2 value which is
not suﬃcient condition for the model to have high predictive
power [23]. The regression summary of diﬀerent 3D-QSAR
models obtained at default parameters and after region fo-
cusing are presented in Tables 2 and 3,r e s p e c t i v e l y .T h ep r e -
dictedpIC50 valuesfortrainingandtestsetfromCoMFAand
CoMSIA models are given in Tables 4 and 5,r e s p e c t i v e l y .
In 3D-QSAR, the determination of the bioactive con-
former and molecular alignment of the compounds is an im-
portant step. In ligand-based techniques, the minimum en-
ergy conformers are often used as bioactive conformer. In
contrast, the binding poses obtained from cocrystal struc-
tureareusedinreceptor-guidedtechniques.Here,bothtech-
niques were used. The statistical results indicate that confor-
mation obtained from molecular docking is more reliable.
In Figure 1, the yellow conformer displays systematic search-
based minimum energy conformer while the red structure
shows docked conformer. The ﬁndings are reasonable as the
oxygen attached with benzyl group of docked conformer is
more closed to amino acid (Asp1086) that facilitates an H-
bonding between –NH of Asp-1086 and this oxygen atom
of the inhibitor; but in case of minimum energy conformer
(yellow), the benzyl moiety is quite far and disfavors such in-
teractions.
3.5. TheCoMFAcontourmaps
Figures 2 and 3 show the electrostatic and steric contour
maps of the best models based on receptor-guided alignment
scheme. The electrostatic interactions are represented byM. Muddassar et al. 5
Table 2: Statistical summary of diﬀerent PLS analysis. (GS: geometrical scheme; SE: standard error of estimate; n.: number of components;
F:F i s c h e r ’ sF value for test of signiﬁcance; r2
bs:c o e ﬃcient of determination after 100 bootstrapping runs; SD: standard deviation; Field
contribution: (S) steric ﬁeld, (E) electrostatic ﬁeld, (H) hydrophobic ﬁeld, (D) H-bond donor ﬁeld, and (A) H-bond acceptor ﬁeld.).
Analysis GS Field q2 n. r2 F SE r2
bs SD r2
pred
CoMFA LB S 0.52 4 0.84 50.12 0.23 — — —
CoMFA LB E 0.38 3 0.73 34.7 0.30 — — —
CoMFA LB 0.49S/0.51E 0.52 4 0.88 70 0.20 0.91 0.1 0.67
CoMFA RG S 0.38 4 0.72 24.5 0.31 — — —
CoMFA RG E 0.42 7 0.86 33.12 0.22 — — —
CoMFA RG 0.45/0.55 0.53 6 0.95 113.6 0.13 0.97 0.00 0.67
C o M S I A L B S 0 . 2 7 3— — ————
C o M S I A L B E 0 . 3 6 1— — ————
C o M S I A L B H 0 . 3 2 4— — ————
C o M S I A L B D 0 . 0 0 1— — ————
C o M S I A L B A 0 . 3 3 2— — ————
C o M S I A L B E / S 0 . 3 7 2— — ————
C o M S I A L B 0 . 6 0 E / 0 . 4 0 A 0 . 4 1 2— — ————
C o M S I A L B 0 . 7 3 E / 0 . 2 7 D 0 . 4 1 3— — ————
C o M S I A L B 0 . 5 1 E / . 4 9 H 0 . 3 9 2— — ————
CoMSIA LB 0.41E/0.27S/0.31A 0.42 4 0.80 39.2 0.26 0.85 0.04 0.57
C o M S I A L B E / A / D 0 . 4 1 2— — ————
C o M S I A R G S 0 . 3 7 1— — ————
C o M S I A R G E 0 . 4 6 4— — ————
C o M S I A R G H 0 . 3 5 3— — ————
C o M S I A R G D 0 . 1 5 5— — ————
C o M S I A R G A 0 . 3 9 3— — ————
C o M S I A R G 0 . 7 1 E / 0 . 2 9 S 0 . 4 6 5— — ————
CoMSIA RG 0.66E/0.34A 0.52 5 0.85 41.2 0.23 0.89 0.04 0.57
C o M S I A R G E / D 0 . 4 8 6— — ————
C o M S I A R G 0 . 5 7 E / 0 . 4 3 H 0 . 4 8 5— — ————
CoMSIA RG 0.54E/0.21S/0.25A 0.51 5 0.86 45.4 0.22 0.9 0.03 0.64
C o M S I A R G E / A / D 0 . 4 7 6— — ————
Table 3: Statistics of diﬀerent PLS analysis after region focusing. (GS: geometrical scheme; SE: standard error of estimate; n.: number
of components; F:F i s c h e r ’ sF value for test of signiﬁcance; r2
bs:c o e ﬃcient of determination after 100 bootstrapping runs; SD: standard
deviation;Fieldcontribution:(S)stericﬁeld,(E)electrostaticﬁeld,(H)hydrophobicﬁeld,(D)H-bonddonorﬁeld,and(A)H-bondacceptor
ﬁeld.).
Analysis GS Field Grid spacing q2 n. r2 F SE r2
bs SD r2
pred
CoMFA LB S 0.5 ˚ A 0.59 5 0.84 40.41 0.234 0.89 0.11 0.65
CoMFA LB E 0.5 ˚ A 0 . 1 32— — — ———
CoMFA LB 0.57S/0.43E 0.5 ˚ A 0.56 4 0.84 49.62 0.235 076 0.13 0.68
CoMFA LB S 1.5 ˚ A 0.25 1 0.36 23.40 0.450 — — —
CoMFA LB E 1.5 ˚ A −0.03 1 — — — — — —
CoMFA LB 0.35S/0.65E 1.5 ˚ A 0.38 2 0.51 21.20 0.40 — — —
CoMFA RG S 0.5 ˚ A 0.41 4 0.71 23.47 0.315 — — —
CoMFA RG E 0.5 ˚ A 0.42 7 0.87 33.11 0.220 — — —
CoMFA RG 0.47S/0.53E 0.5 ˚ A 0.55 6 0.94 97.78 0.145 0.96 0.02 0.67
CoMFA RG S 1.5 ˚ A 0.44 4 0.65 17.93 0.345 — — —
CoMFA RG E 1.5 ˚ A 0.11 4 0.26 3.32 0.505 — — —
CoMFA RG 0.45S/0.50E 1.5 ˚ A 0.29 3 0.60 18.99 0.370 — — —6 Journal of Biomedicine and Biotechnology
Table 4: Experimental and predicted activities with their residuals by CoMFA and CoMSIA analyses of the training set.
n.
CoMFA CoMSIA
Experimental Predicted Predicted
pIC50 pIC50 Residual pIC50 Residual
1 5.706 5.553 0.153 5.646 0.060
2 6.286 6.296 −0.010 6.172 0.114
3 5.870 5.948 −0.078 5.781 0.089
4 5.480 5.888 −0.408 5.814 −0.334
6 5.979 5.365 0.614 5.421 0.558
9 5.202 5.275 −0.073 5.074 0.128
10 5.963 6.200 −0.237 6.199 −0.236
11 6.218 6.191 0.027 6.135 0.083
12 6.650 6.276 0.374 6.330 0.320
13 6.292 6.065 0.227 5.849 0.443
14 5.910 5.870 0.040 5.842 0.068
15 6.465 6.487 −0.022 6.363 0.102
16 5.674 5.927 −0.253 5.787 −0.113
18 5.484 5.473 0.011 5.589 −0.105
19 5.238 5.102 0.136 5.579 −0.341
20 5.550 5.615 −0.065 5.625 −0.075
21 6.047 6.015 0.032 6.226 −0.179
22 5.349 5.544 −0.195 5.754 −0.405
24 6.668 6.571 0.097 6.474 0.194
25 5.870 6.034 −0.164 5.832 0.038
26 5.777 5.929 −0.152 6.416 −0.639
27 6.606 6.586 0.02 6.498 0.108
28 5.979 5.981 −0.002 5.676 0.303
29 5.455 5.471 −0.016 5.562 −0.107
30 5.421 5.473 −0.052 5.604 −0.183
32 6.656 6.366 0.290 6.297 0.359
33 6.111 6.366 −0.255 6.297 −0.186
35 5.740 5.706 0.034 6.068 −0.328
37 5.886 5.934 −0.048 5.864 0.022
38 5.857 5.828 0.029 5.763 0.094
39 6.924 6.826 0.098 6.785 0.139
40 6.642 6.826 −0.184 6.785 −0.143
41 6.939 7.009 −0.070 6.951 −0.012
42 7.092 7.032 0.060 6.916 0.176
43 6.987 7.012 −0.025 7.008 −0.021
46 7.051 6.950 0.101 7.130 −0.079
47 7.222 7.325 −0.103 7.126 0.096
48 6.780 6.763 0.017 6.881 −0.101
50 6.830 6.776 0.054 6.842 −0.012
51 6.658 6.648 0.010 6.806 −0.148
52 6.577 6.547 0.030 6.429 0.148
53 6.279 6.328 −0.049 6.298 −0.019
54 6.256 6.328 −0.072 6.298 −0.042M. Muddassar et al. 7
Table 5: Experimental and predicted activities with their residuals by CoMFA and CoMSIA analyses of the test set.
n.
CoMFA CoMSIA
Experimental Predicted Predicted
pIC50 pIC50 Residual pIC50 Residual
5 5.456 5.404 0.052 5.536 −0.080
7 5.644 5.779 −0.135 5.811 −0.167
8 5.955 6.015 −0.060 5.787 0.168
17 6.009 5.966 0.043 5.819 0.190
23 6.483 6.274 0.209 6.304 0.179
31 5.775 5.703 0.072 5.728 0.047
34 6.979 6.269 0.710 6.205 0.774
36 5.469 5.696 −0.227 5.924 −0.455
44 7.041 7.080 −0.039 7.227 −0.186
45 6.936 6.950 −0.014 7.130 −0.194
49 6.625 6.902 −0.277 6.834 −0.209
Figure 1: Comparison of minimum energy (yellow) and docking
based (red) conformers.
Figure 2: CoMFA electrostatic maps with the most (red) and least
(orange) active compound within the active site.
Figure 3: CoMFA steric maps with the most (red) and least (or-
ange) active compound within the active site.
red- and blue-colored contours while steric interactions are
representedbygreenandyellowcoloredcontours.Inelectro-
static ﬁeld, blue color contour represents region where elec-
tropositivegroupenhancestheactivity,whereasred-colorre-
gion likes electron-rich groups to increase the biological ac-
tivity.Incaseofstericinteractions,thegreenregiondemands
bulky substituents to enhance the activity, while in yellow
contours, bulky substituents decrease the activity.
The most potent compound-47 (red color) and least-
active compound-9 (orange color) of the series with CoMFA
contour maps have been superimposed in the active site
of the receptor protein. Figure 2 shows that red polyhe-
drons locate the region where electron-rich group will en-
hance the inhibitory activity, and vice versa for blue poly-
hedron. Therefore, the phenyl ring in compound-47 might
be responsible for its higher activity than methoxy group of
compound-9becauseitmighthavetheπ-π interactionswith
the phenyl ring of phenyl alanine (Phe1010) amino acid. The8 Journal of Biomedicine and Biotechnology
red contour around 1–3 carbon of cyclobutane also demands
the electron-rich group for higher potency. Compound-47
has amino group at C-3 position which might be responsi-
ble for its higher activity than least-active compound-9. It
is also clear in most of compounds from the dataset that
electron-rich group at this position have higher activity than
compound-9. In Figure 3, green polyhedron locates the re-
gion where bulky substitutent would increase the inhibitory
activity and yellow polyhedron where the steric bulk is not
requiredforhighpotencyofthecompounds.Thesmallgreen
contour near the phenyl ring of compound-47 explains its
higher activity than compound-9. Similarly, the green con-
touraround2and3carbonofcyclobutanerequiresthebulky
substitutent to be highly active. Thus the bulky substitutent
at this position in dataset favors the higher inhibitory activ-
ity of the compounds than compound-9. Yellow polyhedron
below theplaneofphenylring andcyclopropane requiresthe
small group to be more active.
3.6. CoMSIAcontourmaps
TheCoMSIAcontourmapswerealsodevelopedonthemod-
els based on the geometrical scheme 2. Figures 4, 5,a n d6
show the steric electrostatic and H-bond acceptor contour
mapssuperimposedintheactivesiteoftheIGF-1R.InCoM-
SIA method, steric and electrostatic contours maps have the
same meaning as that of CoMFA contour maps whereas H-
bond acceptor contours are represented by magenta and red
colors.Magentafavors H-bond acceptorgroupwhilereddis-
favors.Thestericandelectrostaticmapsaremoreorlesssim-
ilar to the corresponding CoMFA models (Figures 2 and 3,
resp.) except that there is a small green contour near phenyl
ring of compound-47 in CoMFA model. In Figure 6, the ma-
genta contour around C-2 and C-3 position of cyclobutane
favors the H-bond accepting group to enhance the inhibitory
activity of the molecules. Thus the H-bond accepting sub-
stituent at C-4 position might enhance inhibitory activity of
the compounds through H-bonding with Glycine (Gly1008)
or Valine (Val1013).
4. CONCLUSION
Ac o m p a r a t i v eC o M F Aa n dC o M S I Am o d e l sw e r ed e v e l -
opedfortheseriesofpotentIGF-1Rinhibitors.Ligand-based
a n dr e c e p t o r - g u i d e dp r o t o c o l sw e r ea p p l i e dt od e v e l o pt h e
models. Receptor-guided alignment gave models with better
statistics than the ones from the ligand-based approach, pre-
sumably because the alignment using receptor information
is more realistic. Moreover, the interpretation of receptor-
guided models are directly associated with the receptor in-
formation. That is, in general, the superposition of a CoMFA
or CoMSIA contour map inside the receptor shows reason-
able correspondence between the contour map property and
the physical property of surrounding active site region. This
provides more detailed understanding about the interaction
between the series of inhibitors and IGF-1R. The informa-
tion drawn here can be used to design new inhibitors of
IGF-1R.
Figure 4: CoMSIA electrostatic maps with the most (red) and least
(orange) active compound within the active site.
Figure 5: CoMSIA steric maps with the most (red) and least (or-
ange) active compound within the active site.
Figure 6: CoMSIA H-bond acceptor map with the most (red) and
least (orange) active compound within the active site.M. Muddassar et al. 9
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